IL6 and endometrial serous adenocarcinoma: This finding contrasts with some previous studies; for example, Bellone et al. reported higher IL6 levels in endometrial cancer patients, particularly in those with uterine papillary serous carcinoma, a more aggressive type of type 2 endometrial cancer [65].